Behavioral Neuroscience – Products

BioMed X announces the successful completion of its first joint research project with Boehringer Ingelheim in neuroscience.

WeWALK has joined Microsoft’s AI for Accessibility programme to accelerate WeWALK’s capability by developing and validating a human behaviour model and creating a Voice Assistant for visually impaired users, providing the right mobility information when needed and allowing for even greater control of the WeWALK mobility experience.

Postnova Analytics has published a new white paper that details how multi-detector Asymmetrical Field Flow Fractionation (AF4) and Electrical AF4 (EAF4) techniques are transforming the separation and characterization of viruses and antibodies.

Lyndra Therapeutics has filed an Investigational New Drug (IND) application with the Food and Drug Administration (FDA) for its ultra-long-acting oral therapy to treat schizophrenia (risperidone).

BioMed X is collaborating with Boehringer Ingelheim to investigate myelination deficits of the adolescent brain in connection with the development of schizophrenia.

It is hoped that AI screening of human emotions will eventually help eliminate mental diseases and depression.

Expanding freely behaving microscopy by delivering increased resolution, signal-to-noise and optical sectioning through data correlation.

Johannes Kohl awarded prize for his work in the field of neurobiology.

A major international FDA-led study confirms CellOPTIQ® High Content Assay as leading in vitro platform to assess cardiotoxicity in new drugs.